Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immunovaccine's DepoVax™ Technology Underpins New Experimental Therapy for Cancers

Published: Wednesday, April 09, 2014
Last Updated: Wednesday, April 09, 2014
Bookmark and Share
IMV vaccine adjuvant technology of choice for Dana-Farber's HPV-related cancer clinical trial.

Immunovaccine Inc. has announced that its DepoVax™ adjuvanting technology will underlie the design of a new cancer vaccine trial that will be conducted by the Dana-Farber Cancer Institute to treat cervical and head and neck cancer.

In a competitive process, Dana-Farber has been awarded a research grant of $1.2 million for clinical evaluation of its cancer vaccine.

The grant from Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation was awarded to a team of Dana-Farber researchers in a ceremony last evening at the 2014 American Association for Cancer Research (AACR) annual meeting.

The three-year grant will be used to fund a Phase I clinical trial of the group's peptide cancer antigen formulated in DepoVax in patients with HPV-related cervical and head and neck cancers.

The grant was awarded based on a proposal highlighting the potential of Dana-Farber's proposed cancer antigen identified by a new mass spectrometry method termed Poisson detection MS and Immunovaccine's DepoVax platform.

The DepoVax data focused on clinical trial results with DPX-Survivac, which demonstrated strong immune response activity in cancer patients and the immune enhancement observed with the immune modulating agent cyclophosphamide.

Dana-Farber's proposed Phase I study in HPV-related cancers will use the same approach, formulating the Institute's peptide-based vaccine in DepoVax and administering it to patients in combination with cyclophosphamide.

"We believe that the grant committee was encouraged by novel interdisciplinary science in conjunction with the powerful immunogenicity data that Immunovaccine has collected to date with our DPX-Survivac cancer vaccine candidate," stated Marc Mansour, Ph.D., chief operating officer of Immunovaccine. "We are excited to work with the talented team at Dana-Farber and add value to their clinical program with our DepoVax technology. Our previous work with DPX-Survivac gives us confidence that DepoVax has the potential to induce strong immunological responses to their novel antigen to enable the vaccine in the clinic."

The SU2C-Farrah Fawcett Foundation HPV Translational Research Team Grant provides three years of funding for a multidisciplinary, translational cancer research project that addresses critical problems in HPV-related cancers and that can deliver near-term patient benefit through investigation by a team of two expert investigators.

To be considered for the grant, research project designs were required to include clear plans indicating how the work will be translated into the clinic and deliver near-term benefits to patients with HPV-related cancers. HPV infection causes virtually all cervical cancers, and many anal, vaginal, vulvar, penile, and oropharyngeal cancers.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immunovaccine Signs Research Agreement with OncoTherapy Science
Immunovaccine Inc. announced that it has signed a collaborative research agreement with OncoTherapy Science Inc. to explore the efficacy of their novel peptide cancer antigen in Immunovaccine's DepoVax™ vaccine delivery and enhancement platform.
Tuesday, November 30, 2010
Scientific News
Russian TB Thrives Within Macrophages
MIPT researchers have identified features of mycobacterium tuberculosis strains that may explain their success.
New Inflammatory Disease Discovered
NIH researchers have discovered a rare and potentially deadly disease - otulipenia - the mostly affects children.
Pinpointing Key Influenza-Fighting Immune Trigger
Immunologists have identified the protein trigger that recognises influenza virus infection in cells and triggers their death.
Sweet Spot of Human Immune System
Scientists propose answer to how the human immune system scales its response in proportion to threat to make it 'just right'.
Examining Immune Memory
Researchers investigate the 'storage/research for the future' functions of antibodies and understanding of B cells.
Characterizing the Mouse Gut Microbiome
Study establishes the first public collection of bacteria from the intestine of mice.
Microchip Tech Improves Nanomaterial Safety Screening
Platform developed at UCLA uses lab-on-a-chip technology to predict how hazardous engineered nanomaterials might be.
Immune-Cell Population Predicts Immunotherapy Response in Melanoma
All patients with high levels of one immune-cell type responded to treatment.
Bone Marrow Transplants Without Using Chemotherapy
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects.
Oral Immunotherapy Is Safe, Effective Treatment for Peanut-Allergic Preschoolers
Study demonstrates the potential of peanut OIT to suppress allergic immune responses to peanut.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!